Pulmonary Fibrosis in India and UAE | Complete Patient Guide

• CONFIRMED IPF DIAGNOSIS: Multidisciplinary ILD board consensus based on HRCT UIP pattern (± surgical lung biopsy via VATS) after exclusion of secondary causes (connective tissue disease, drug toxicity, hypersensitivity pneumonitis)

• ANTIFIBROTIC THERAPY CANDIDATES: FVC ≥50% predicted, DLCO ≥30% predicted, confirmed UIP/probable UIP on HRCT, NYHA/MRC dyspnea grade II–III, absence of advanced hepatic impairment (nintedanib) or severe photosensitivity contraindication (pirfenidone)

• TRANSPLANT EVALUATION CANDIDATES: Progressive disease despite ≥6 months of antifibrotic therapy, FVC <80% predicted with ≥10% relative decline over 12 months, DLCO <40% predicted, 6-minute walk test desaturation below SpO₂ 88%, or acute exacerbation requiring hospitalization

• REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL: HRCT chest (thin-slice ≤1.5 mm), full pulmonary function tests (spirometry, plethysmography, DLCO), 6-minute walk test with oximetry, echocardiography (to assess pulmonary hypertension — a key modifier of transplant candidacy), CT pulmonary angiography or V/Q scan (to exclude chronic thromboembolic disease), standard metabolic panel, LFTs, renal function, and ANA/RF/anti-CCP/anti-Scl70 autoimmune panel

• FOR TRANSPLANT EVALUATION: Right heart catheterization (mPAP, PAWP, PVR), coronary angiography (if age >50 or cardiovascular risk factors), bone densitometry, upper GI endoscopy, age-appropriate cancer screening, psychosocial assessment, and body composition/nutritional assessment (BMI <16 or >35 kg/m² are relative contraindications)

• CONTRAINDICATIONS TO ANTIFIBROTIC THERAPY: Active smoking (relative; cessation mandatory), severe hepatic impairment (Child-Pugh B/C for nintedanib), active peptic ulceration, or documented intolerance to both agents

• ABSOLUTE CONTRAINDICATIONS TO LUNG TRANSPLANTATION: Active or recent malignancy (<5-year disease-free interval for most cancers), uncontrollable systemic infection, significant extrapulmonary organ dysfunction (GFR <40 mL/min, severe LV dysfunction EF <40%, cirrhosis), active substance abuse, documented medical non-adherence, untreatable severe psychiatric illness, absence of adequate social support system

ANTIFIBROTIC PHARMACOTHERAPY Nintedanib (Ofev®): A triple tyrosine kinase inhibitor administered orally at 150 mg twice daily with food. It inhibits PDGFR-α/β, FGFR-1/2/3, and VEGFR-1/2/3 — receptors that mediate fibroblast proliferation, differentiation, and migration. In the INPULSIS trials, nintedanib reduced annual FVC decline by 50% (approximately 50 mL/year vs. 200 mL/year on placebo). Key adverse effects include diarrhea (60–65% of patients; managed with loperamide and dose reduction to 100 mg BID), nausea, and elevated hepatic transaminases requiring monthly LFT monitoring in the first 3 months.

Pirfenidone (Esbriet®): An oral antifibrotic with anti-inflammatory and antioxidant properties acting primarily through TGF-β1 pathway suppression, dosed at 2,403 mg/day in three divided doses after titration. ASCEND and CAPACITY trials demonstrated a 47% reduction in FVC decline versus placebo. Key adverse effects include photosensitivity (mandatory daily broad-spectrum SPF 50+ sunscreen), gastrointestinal intolerance, and fatigue. Dose titration over 3 weeks reduces GI side effects.

Combination therapy (nintedanib + pirfenidone) is under investigation; current evidence from the INJOURNEY trial suggests pharmacokinetic compatibility and additive tolerability — specialists at partner centers will individualize based on the patient's tolerance profile.

OXYGEN THERAPY & PULMONARY REHABILITATION Ambulatory long-term oxygen therapy (LTOT) is initiated when resting SpO₂ ≤88% or exercise-induced desaturation is documented. Supervised pulmonary rehabilitation programs — combining endurance and resistance exercise with respiratory physiotherapy and nutritional counseling — improve 6MWT distance by 30–50 meters and patient-reported quality of life scores, though they do not alter disease trajectory. GAF Healthcare partner centers offer structured 2–4 week intensive inpatient or day-program pulmonary rehabilitation modules for traveling patients.

TREATMENT OF COMORBIDITIES Pulmonary hypertension complicating IPF is managed with careful consideration — non-selective pulmonary vasodilators (sildenafil, ambrisentan) are not routinely indicated and may worsen V/Q mismatch; inhaled treprostinil (Tyvaso®) showed benefit in the INCREASE trial for ILD-associated PH and is available at partner centers. Gastroesophageal reflux disease (GERD), present in >70% of IPF patients and implicated in micro-aspiration-driven acute exacerbations, is treated aggressively with high-dose PPIs and, in selected cases, laparoscopic anti-reflux surgery. Obstructive sleep apnea, obesity, and depression are addressed as integral components of comprehensive ILD management.

ACUTE EXACERBATION MANAGEMENT Acute exacerbations (AE-IPF) — defined as rapid respiratory deterioration with new bilateral ground-glass opacities on HRCT superimposed on a UIP background — are treated with high-dose intravenous methylprednisolone (500–1,000 mg/day for 3 days), empiric broad-spectrum antibiotics, and lung-protective mechanical ventilation only as a bridge to transplant, given the near-prohibitive mortality of AE-IPF in non-transplant candidates on invasive ventilation.

LUNG TRANSPLANT EVALUATION & LISTING The transplant evaluation pathway involves a structured 2–3 week assessment at the transplant center encompassing all organ-system investigations, multidisciplinary team (MDT) review including pulmonology, thoracic surgery, cardiology, nephrology, infectious disease, psychiatry, and social work, and listing decision per ISHLT 2021 consensus criteria. Bilateral sequential lung transplantation (BSLT) is the preferred procedure for IPF over single-lung transplantation (SLT), as BSLT confers superior long-term survival and eliminates the risk of native-lung complications in the immunosuppressed host. The surgical technique employs cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) support as required, with sequential bronchial anastomoses, pulmonary artery, and pulmonary vein/atrial cuff anastomoses performed via bilateral antero-lateral thoracotomies (clamshell approach) or bilateral thoracoscopic-assisted techniques at advanced centers.

Post-transplant immunosuppression follows the standard triple-drug protocol: calcineurin inhibitor (tacrolimus, targeting trough levels of 10–15 ng/mL initially), antimetabolite (mycophenolate mofetil 1,500 mg BID or azathioprine), and corticosteroids (prednisolone tapered to 5–10 mg/day by 6 months). Chronic lung allograft dysfunction (CLAD) — particularly bronchiolitis obliterans syndrome (BOS) — remains the principal long-term threat, affecting ~50% of recipients by 5 years and managed with azithromycin, extracorporeal photopheresis, or anti-reflux surgery as clinically indicated.

PHASE 1 — PRE-ARRIVAL COORDINATION (2–4 weeks before travel) GAF Healthcare's medical coordinators review all existing diagnostic records (HRCT, PFTs, bronchoscopy/biopsy reports, echocardiography) via a secure digital portal. The in-house medical team prepares a provisional treatment pathway — antifibrotic initiation vs. transplant evaluation — and selects the appropriate partner center. The patient receives a pre-travel checklist specifying required investigations to be completed at home to avoid duplication and unnecessary cost. e-Medical visa (India) or UAE entry visa documentation is prepared in parallel.

PHASE 2 — ARRIVAL & INITIAL ASSESSMENT (Days 1–3) The patient is received at the airport by a GAF Healthcare coordinator and transferred directly to the partner hospital. On Day 1, pulmonology admission is completed, baseline vitals, resting and ambulatory SpO₂, and 6MWT are recorded. Day 2 involves confirmatory investigations: thin-slice HRCT chest review by an ILD-specialist radiologist, full PFTs with bronchodilator response, echocardiography, and a comprehensive laboratory panel including LFTs, renal function, CBC, BNP/NT-proBNP, and an updated autoimmune screen. Day 3: multidisciplinary ILD board review, treatment decision communicated to patient and family with written informed consent.

PHASE 3A — ANTIFIBROTIC THERAPY PATHWAY (Days 4–14) The chosen antifibrotic agent is initiated under supervision. For pirfenidone, a 2-week in-country titration schedule (801 mg TID × 1 week → 1,602 mg TID × 1 week → 2,403 mg TID thereafter) allows assessment of GI tolerance and photosensitivity. For nintedanib, full-dose 150 mg BID initiation with LFT checks at Day 7 and Day 14. Pulmonary rehabilitation sessions begin on Day 4–5. Supplemental oxygen titration, GERD management, and sleep study (if indicated) are conducted during this phase. Milestone: Patient achieves therapeutic antifibrotic dose, tolerability confirmed, rehabilitation baseline established. Fit-to-fly assessment at Day 14–21 based on SpO₂ stability on ambulatory oxygen (if required), HRCT stability, and confirmed outpatient pharmacy access in home country.

PHASE 3B — TRANSPLANT EVALUATION PATHWAY (Days 4–21) Full organ-system assessment over 2–3 weeks: right heart catheterization (Day 4–5), coronary angiography (if indicated, Day 6–7), upper GI endoscopy, renal clearance study, bone densitometry, colonoscopy (age-appropriate), and full psychosocial assessment. MDT listing conference at Day 18–21 with formal listing decision communicated. If listed, the patient is counseled on average wait times (variable by blood group and center volume), and a plan for long-term follow-up (remote monitoring + periodic return visits) is established. Patients not immediately transplanted return home on optimal medical therapy and remote monitoring.

PHASE 4 — LUNG TRANSPLANTATION (IF ORGAN BECOMES AVAILABLE): Days 1–21 post-transplant in ICU/step-down Day 0 (Surgery): Bilateral sequential lung transplantation under general anesthesia ± ECMO support; operative time 6–10 hours. Days 1–3: ICU care — mechanical ventilation weaning per extubation readiness protocol, hemodynamic optimization, bronchoscopy on Day 1–2 to assess anastomotic healing and clear secretions. Days 4–7: Step-down unit, mobilization begins with physiotherapy, oral tacrolimus/MMF/prednisolone initiated, tacrolimus trough levels monitored daily. Days 8–14: Ambulation in corridor, supervised inspiratory muscle training, nutritional optimization. Days 15–21: Discharge planning — immunosuppression education, infection prophylaxis regimen (trimethoprim-sulfamethoxazole, valganciclovir, azole antifungal), spirometry home-monitoring kit provided.

PHASE 5 — POST-DISCHARGE & FIT-TO-FLY (Weeks 4–12 post-transplant) Outpatient clinic visits at 1 week, 4 weeks, 8 weeks post-discharge. Tacrolimus trough adjustments, LFTs, renal function, and chest X-ray at each visit. Surveillance bronchoscopy with BAL and transbronchial biopsy at 4–6 weeks post-transplant to exclude acute rejection or infection. Fit-to-fly clearance for intercontinental flight (>8 hours) is granted at minimum 8–10 weeks post-transplant, contingent on stable graft function (FEV₁ ≥60% of predicted post-transplant best, no active rejection or infection, independent ambulation, oxygen independence at rest). A detailed hand-over medical summary, immunosuppression schedule, and emergency contact protocol is provided to the patient's home pulmonologist.